1548439-51-5
1548439-51-5 structure
- Name: Lefitolimod
- Chemical Name: Lefitolimod
- CAS Number: 1548439-51-5
- Molecular Formula:
- Molecular Weight:
- Catalog: Signaling Pathways Anti-infection HIV
- Create Date: 2023-02-02 18:25:05
- Modify Date: 2024-04-07 10:03:00
-
Lefitolimod (MGN 1703) is a DNA-based TLR9 agonist and an immune surveillance reactivator. Lefitolimod induces HIV-specific immune responses and can be used for the research of cancer and HIV-1[1][4].
| Name | Lefitolimod |
|---|
| Description | Lefitolimod (MGN 1703) is a DNA-based TLR9 agonist and an immune surveillance reactivator. Lefitolimod induces HIV-specific immune responses and can be used for the research of cancer and HIV-1[1][4]. |
|---|---|
| Related Catalog | |
| Target |
TLR9 HIV-1 |
| In Vitro | Lefitolimod (MGN 1703) might foster innate and adaptive immune response and thus improve immune-mediated control of residual cancer disease[1]. Lefitolimod targets TLR9-positive pDCs and triggers their secretion of IFN-α to activate the effector cells of innate immunity subsequently leading to an elevated systemic level of IP-10, a chemotactic and angiostatic protein[2]. Lefitolimod (MGN1703) (1 μM; 48 h) stimulates cytokine secretion (interferon (IFN)-α, IFN-γ, interleukin (IL)-12, IL-6, and IL-2) and activates immune cells by increased expression of CD80, CD40, human leukocyte antigen (HLA)-DR and ICAM-1[3]. |
| In Vivo | Lefitolimod (MGN1703) (2.5 and 60 μg/day; i.p.; daily for 7 days) raises IL-12p40 levels in mice sera without toxicity[3]. Animal Model: Female C57BL6 mice[3] Dosage: 2.5 and 60 μg/day Administration: Intraperitoneal injection, once daily for 7 days Result: Were able to raise IL-12p40 levels in mice sera. |
| References |
| No Any Chemical & Physical Properties |